問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

China Medical University Hospital-Taipei (在職)

Division of Thoracic Medicine

更新時間：2023-09-19

夏德椿Hsia, Te-Chun
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years

  • d1914@mail.cmuh.org.tw

Recruiting Trial

51Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

夏德椿

China Medical University Hospital

Division of Thoracic Medicine

List

117Cases

2010-02-01 - 2011-10-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2012-03-02 - 2014-08-31

Phase III

LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy

  • Condition/Disease

    Lung cancer

  • Test Drug

    BIBW 2992 (Afatinib)

Participate Sites
8Sites

Terminated8Sites

2011-12-07 - 2014-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2015-11-01 - 2017-10-31

Phase III

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

  • Condition/Disease

    Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

  • Test Drug

    ASP8273

Participate Sites
9Sites

Terminated9Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2011-07-01 - 2016-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-05-01 - 2014-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2017-05-01 - 2023-10-30

Phase III

Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy

  • Condition/Disease

    NSCLC

  • Test Drug

    Nivolumab (BMS-936558),Ipilimumab (BMS-734016)

Participate Sites
16Sites

Terminated14Sites

黃煦晴
Taipei Veterans General Hospital

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

1 8 9 10 11 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB